Clinical strategies for amyloid A amyloidosis secondary to rheumatoid arthritis

References

• Pepys MB, Hawkins PN. Amyloidosis. In: Wane11 DA, Cox TM, Firth JD, Benz EJ Jr, editors. Oxford textbook of medicine. 4th ed. Oxford: Oxford University Press; 2003. p. 162–73.
   Google Scholar
• Hirschfield GM, Hawkins PN. Amyloidosis: new strategies for treatment. Int J Biochem Cell Biol. 2003;35:1608–13.
   PubMed Web of Science ®Google Scholar
• Cunnane G. Amyloid precursors and amyloidosis in inflammatory arthritis. Curr Opin Rheumatol. 2001;13:67–73.
   PubMed Web of Science ®Google Scholar
• Sandhu V, Allen SC. The effect of age, seropositivity and disease duration on autonomic cardiovascular reflexes in patients with rheumatoid arthritis. Int J Clin Pract. 2004;58:740–5.
   PubMed Web of Science ®Google Scholar
• Calguneri M, Ureten K, Akif Ozturk M, Onat AM, Ertenli I, Kiraz S, et al. Extra-articular manifestations of rheumatoid arthritis: results of a university hospital of 526 patients in Turkey. Clin Exp Rheumatol. 2006;24:305–8.
   PubMed Web of Science ®Google Scholar
• Voskuyl AE. The heart and cardiovascular manifestations in rheumatoid arthritis. Rheumatology. 2006;45:iv4–7.
   Google Scholar
• Cunnane G, Whitehead AS. Amyloid precursors and amyloidosis in rheumatoid arthritis. Bailliere's Clin Rheumatol. 1999;13:615–28.
   PubMed Web of Science ®Google Scholar
• Gertz MA, Kyle RA. Secondary systemic amyloidosis: response and survival in 64 patients. Medicine. 1991;70:246–56.
   PubMed Web of Science ®Google Scholar
• Rocken C, Radum D, Glasbrenner B, Malfertheiner P, Roessner A. Generalized AA-amyloidosis in a 58-year-old Caucasian women with an 18-month history of gastrointestinal tuberculosis. Virchows Arch. 1999;434: 95–100.
   Google Scholar
• Nakamura T, Baba S, Yamamura Y, Tsuruta T, Matsubara S, Tomoda K, et al. Combined treatment with cyclophosphamide and prednisolone is effective for secondary amyloidosis with SAA17/7 genotype in a patient with rheumatoid arthritis. Mod Rheumatol. 2000;10:160–4.
   PubMedGoogle Scholar
• Husby G, Marhaug G, Dowton B, Sletten K, Sipe JD. Serum amyloid A (SAA): biochemistry, genetics and the pathogenesis of AA amyloidosis. Amyloid. 1994;1:119–37.
   Google Scholar
• Emery P, Luqmani R. The validity of surrogate markers in rheumatic disease. Br J Rheumatol. 1993;32(Suppl 3):3–8.
   PubMedGoogle Scholar
• Lachmann RI, Goodman RIB, Gilbertson JA, Gallimore JR, Sabin CA, Gillmore JD, et al. Natural history and outcome in systemic AA amyloidosis. N Engl J Med. 2007;356:2361–71.
   PubMed Web of Science ®Google Scholar
• Rocken C, Shakespeare A. Pathology, diagnosis and pathogenesis of AA amyloidosis. Virchows Arch. 2002;440:111–22.
   PubMed Web of Science ®Google Scholar
• Nakamura T. Amyloid A amyloidosis secondary to rheumatoid arthritis: an uncommon yet important complication. Curr Rheu-matol Rev. 2007;3:231–41.
   Google Scholar
• Malle E, Steinmetz A, Raynes JG. Serum amyloid A (SAA): an acute phase protein and apolipoprotein. Atherosclerosis. 1993; 102:131–46.
   Google Scholar
• Uhlar CM, Whitehead AS. Serum amyloid A, the major verte-brate acute-phase reactant. Eur J Biochem. 1999;265:501–23.
   PubMedGoogle Scholar
• Yamada T, Wada A, Itoh Y, Itoh K. Serum amyloid Al alleles and plasma concentrations of serum amyloid A. Amyloid. 1999;6:199–204.
   PubMed Web of Science ®Google Scholar
• Baba S, Takahashi T, Kasama T, Shirasawa H. Identification of two novel amyloid A protein subsets coexisting in an individual patient of AA-amyloidosis. Biochim Biophys Acta. 1992; 1180:195–200.
   PubMed Web of Science ®Google Scholar
• Baba S, Takahashi T, Kasama T, Fujie M, Shirasawa H. A novel polymorphism of human serum amyloid A protein, SAM gamma, is characterized by alanines at both residues 52 and 57. Arch Biochem Biophys. 1993;303: 361–6.
   Google Scholar
• Xu Y, Yamada T, Satoh T, Okuda Y. Measurement of serum amyloid Al (SAA1), a major isotype of acute phase SAA. Clin Chem Lab Med. 2006;44:59–63.
   PubMed Web of Science ®Google Scholar
• Baba S, Masago SA, Takahashi T, Kasama T, Sugimura H, Tsugane S, et al. A novel allelic variant of serum amyloid A, SAAly: genomic evidence, evolution, frequency, and implication as a risk factor for reactive systemic AA-amyloidosis. Hum Mol Genet. 1995;4:1083–7.
   PubMed Web of Science ®Google Scholar
• Moriguchi M, Terai C, Koseki Y, Uesato M, Nakajima A, Inada S, et al. Influence of genotypes at SAA1 and SAA2 loci on the development and the length of latent period of secondary AA-amyloidosis in patients with rheumatoid arthritis. Hum Genet. 1999;105:360–6.
   PubMed Web of Science ®Google Scholar
• Utku U, Dilek M, Akpolat I, Bedir A, Akpolat T. SAA1 a/a alleles in Behcet's disease related amyloidosis. Clin Rheumatol. 2007;26: 927–9.
   Google Scholar
• Yamada T, Okuda Y, Takasugi K, Wang L, Marks D, Benson MD, et al. An allele of serum amyloid Al associated with amyloidosis in both Japanese and Caucasians. Amyloid. 2003;10:7–11.
   PubMed Web of Science ®Google Scholar
• Moriguchi M, Kaneko H, Terai C, Koseki Y, Kajiyama H, Inada S, et al. Relative transcriptional activities of SAA1 promoters polymorphic at position -13T(T/C): potential association between increased transcription and amyloidosis. Amyloid. 2005;12:26–32.
   PubMed Web of Science ®Google Scholar
• Ajiro J, Narita I, Sato S, Saga D, Hasagawa H, Kuroda T, et al. SAA1 gene polymorphisms and the risk of AA amyloidosis on Japanese patients with rheumatoid arthritis. Mod Rheumatol. 2006;16:294–9.
   PubMedGoogle Scholar
• Gonzalez-Gay MA, Garcia-Porrua C, Hajeer AH. Influence of human leukocyte antigen-DRB1 on the susceptibility and severity of rheumatoid arthritis. Semin Arthritis Rheum. 2002;31:355–60.
   PubMed Web of Science ®Google Scholar
• Fries JF, Wolfe F, Apple R, Erlich H, Bugawan T, Holmes T, et al. HLA-DRB1 genotype associations in 793 white patients from a rheumatoid arthritis inception cohort: frequency, severity, and treatment bias. Arthritis Rheum. 2002;46:2320–9.
   PubMedGoogle Scholar
• Turesson C, Weyand CM, Matteson EL. Genetics of rheumatoid arthritis: is there a pattern predicting extraarticular manifesta-tions? Arthritis Rheum. 2004;51:853–63.
   PubMedGoogle Scholar
• Wakitani S, Imoto K, Murata N, Oonishi H, Ochi T, Yoneda M. An association between the natural course of shoulder joint destruction in rheumatoid arthritis and HLA-DRB1*0405 in Japanese patients. Scand J Rheumatol. 1998;27:146–8.
   PubMed Web of Science ®Google Scholar
• Weyand CM, McCarthy TG, Goronzy JJ. Correlation between disease phenotype and genetic heterogeneity in rheumatoid arthritis. J Clin Invest. 1995;95:2120–6.
   Google Scholar
• Migita K, Nakamura T, Maeda Y, Miyashita T, Origuchi T, Yatsuhashi H, et al. HLA-DRB1*04 alleles in Japanese rheu-matoid arthritis patients with AA amyloidosis. J Rheumatol. 2006;33:2120–3.
   PubMed Web of Science ®Google Scholar
• Wolfe F, Mitchell DM, Sibley JT. The mortality of rheumatoid arthritis. Arthritis Rheum. 1994;37:481–94.
   PubMed Web of Science ®Google Scholar
• Nakamura T, Tsukano M, Tomoda K, Yamamura Y, Shono M, Baba S. Effect of SAA1.3 allele genotype on clinical course in Japanese amyloidotic patients secondary to rheumatoid arthritis. Arthritis Rheum. 2004;50(Suppl):163.
   Google Scholar
• Baba S, Nakai H, Nakamura T, Miyamoto S, Ohta Y, Takahashi T, et al. Novel polymorphisms in the 5'-flanking region of the human serum amyloid Al (SAA1) gene and an association with reactive AA-amyloidosis. Amyloid. 2001;8(Suppl 2):41–3.
   PubMedGoogle Scholar
• Nakamura T, Higashi S, Tomoda K, Tsukano M, Baba S, Shono M. Significance of SAA1.3 allele genotype in Japanese patients with amyloidosis secondary to rheumatoid arthritis. Rheumatol-ogy. 2006;45:43–9.
   Google Scholar
• Nurumi MJ, Ekfors TO, Puntala PV. Secondary amyloidosis of the bladder: a cause of massive hematuria. J Urol. 1987;138:44–5.
   Google Scholar
• Nakamura T, Yamamura Y, Tomoda K, Tsukano M, Baba S. Massive hematuria due to bladder amyloidosis in patients with rheumatoid arthritis: three case reports. Clin Exp Rheumatol. 2003;21:673–4.
   Google Scholar
• Gomez-Casanovas E, Sanmarti R, Sole M, Canate JD, Munoz-Gomez J. The clinical significance of amyloid fat deposit in rheumatoid arthritis. A systemic long-term followup study using abdominal fat aspiration. Arthritis Rheum. 2001;44:66–72.
   Google Scholar
• Suzuki A, Ohosone Y, Obana M, Mita S, Matsuoka Y, Irimajiri S, et al. Cause of death in 81 autopsied patients with rheumatoid arthritis. J Rheumatol. 1994;21:33–6.
   PubMed Web of Science ®Google Scholar
• Ishii W, Matsuda M, Nakamura A, Nakamura N, Suzuki A, Ikeda S. Abdominal fat aspiration biopsy and genotyping of serum amyloid A contribute to early diagnosis of reactive AA amyloi-dosis secondary to rheumatoid arthritis. Intern Med. 2003;42:800–5.
   PubMed Web of Science ®Google Scholar
• Wakhlu A, Krisnani N, Hissatia P, Aggarwal A, Misra R. Prev-alence of secondary amyloidosis in Asian north Indian patients with rheumatoid arthritis. J Rheumatol. 2003;30:948–51.
   Google Scholar
• El Mansoury TM, Hazenberg BP, El Badawy SA, Ahmed AH, Bijzet J, Limburg PC, et al. Screening for amyloid in subcuta-neous fat tissue of Egyptian patients with rheumatoid arthritis: clinical and laboratory characteristics. Ann Rheum Dis. 2002;61:42–7.
   PubMed Web of Science ®Google Scholar
• Kobayashi H, Tada S, Fuchigami T, Okuda Y, Takasugi K, Mi-yamoto T, et al. Secondary amyloidosis in patients with rheumatoid arthritis: diagnostic and prognostic value of gastro-duodenal biopsy. Br J Rheumatol. 1996;35:44–9.
   Google Scholar
• Carmona L, Gonzalez-Alvaro I, Balsa A, Belmonte MA, Tena X, Sanmarti R. Rheumatoid arthritis in Spain: occurrence of extra-articular manifestations and estimates of disease severity. Ann Rheum Dis. 2003;62:897–900.
   PubMed Web of Science ®Google Scholar
• Gonzalez-Alvaro I, Carmona L, Balsa A, Sanmarti R, Belmonte MA, Tena X. Patterns of disease modifying antirheumatic drug use in a Spanish cohort of patients with rheumatoid arthritis. J Rheumatol. 2003;30:697–704.
   Google Scholar
• Misra R, Wakhlu A, Krishnani N, Hissaaria P, Aggarwal A. Prevalence of silent amyloidosis in rheumatoid arthritis and its clinical significance. J Rheumatol. 2004;31:1031–4.
   Google Scholar
• Joss N, McLaughlin K, Simpson K, Boulton-Jones JM. Presen-tation, survival and prognostic markers in AA amyloidosis. Q J Med. 2000;93:535–42.
   Google Scholar
• Tanaka F, Migita K, Honda S, Fukuda T, Mine M, Nakamura T, et al. Clinical outcome and survival of secondary (AA) amyloi-dosis. Clin Exp Rheumatol. 2003;21:343–6.
   PubMed Web of Science ®Google Scholar
• Odabas AR, Cetinkaya R, Selcuk Y, Erman Z, Bilen H. Clinical and biochemical outcome of renal amyloidosis. Int J Clin Pract. 2002;56:342–4.
   Google Scholar
• Gillmore JO, Levitt LB, Jersey MA, PepysMB, Hawkins PN. Amyloid load and clinical outcome in AA amyloidosis in relation to circulating concentration of serum amyloid A protein. Lancet. 2001;358:24–9.
   Google Scholar
• Kitahama M, Koseki Y, Sakurai T, Kamatani N, Terai C. Female is a risk factor for developing AA-amyloidosis in patients with rheumatoid arthritis. Arthritis Rheum. 2007;56(Suppl):410–1.
   Google Scholar
• McGill NW, Tuck R, Hassall JE. Severe autonomic neuropathy in amyloidosis secondary to rheumatoid arthritis. Aust N Z J Med. 1986;16:705–7.
   Google Scholar
• Nakamura T, Tomoda K, Tsukano M, Yamamura Y, Baba S. Gustatory sweating due to autonomic neuropathy in a patient with amyloidosis secondary to rheumatoid arthritis. Mod Rheumatol. 2004;14:498–501.
   Google Scholar
• Mpofu S, Teh LS, Smith PJ, Moots RJ, Hawkins PN. Cytostatic therapy for AA amyloidosis complicating psoriatic spond-yloarthropathy. Rheumatology. 2003;42:362–6.
   Google Scholar
• Visser H, le Cessie S, Vos K, Breedveld FC, Hazes JMW. How to diagnose rheumatoid arthritis early. A prediction model for per-sistent (erosive) arthritis. Arthritis Rheum. 2002;46:357–65.
   PubMed Web of Science ®Google Scholar
• Grateau G, Jeru I, Rouaghe S, Cazeneuve C, Ravet N, Duquesnoy P, et al. Amyloidosis and auto-inflammatory syndromes. Curr Drug Targets Inflamm Allergy. 2005;4:57–65.
   PubMedGoogle Scholar
• Ishii W, Matsuda M, Nakamura N, Katsumata S, Toriumi H, Suzuki A, et al. Phenol Congo red staining enhances the diag-nostic value of abdominal fat aspiration biopsy in reactive AA amyloidosis secondary to rheumatoid arthritis. Intern Med. 2003;42:400–5.
   PubMed Web of Science ®Google Scholar
• Maini RN, Breedveld FC, Kalden JR, Smolen JS, Furst D, Weisman MH, et al. Sustained improvement over two years in physical function, structural damage, and signs and symptoms among patients with rheumatoid arthritis treated with infliximab and methotrexate. Arthritis Rheum. 2004;50:1051–65.
   PubMed Web of Science ®Google Scholar
• Quinn MA, Emery P. Window of opportunity in early rheumatoid arthritis: possibility of altering the disease process with early intervention. Clin Exp Rheumatol. 2003;21(Suppl 31):154–64.
   Google Scholar
• Ahlmen M, Ahlmen J, Svalander C, Bucht H. Cytotoxic drug treatment of reactive amyloidosis in rheumatoid arthritis with special reference to renal insufficiency. Clin Rheumatol. 1987;6:27–38.
   PubMed Web of Science ®Google Scholar
• Berglund K, Thysell H, Keller C. Results, principles and pitfalls in the management of renal AA-amyloidosis: a 10–21 year followup of 16 patients with rheumatic disease treated with alkylating cytostatics. J Rheumatol. 1993;20: 2051–7.
   Google Scholar
• Chevrel G, Jenvrin C, McGregor B, Miossec P. Renal type AA amyloidosis associated with rheumatoid arthritis: a cohort study showing improved survival on treatment with pulse cyclophos-phamide. Rheumatology. 2001;40:821–5.
   PubMed Web of Science ®Google Scholar
• Shapiro DL, Spiera H. Regression of the nephrotic syndrome in rheumatoid arthritis and amyloidosis treated with azathioprine. A case report. Arthritis Rheum. 1995;38:1851–4.
   PubMed Web of Science ®Google Scholar
• Fiter J, Nolla JM, Valverde J, Roig ED. Methotrexate treatment of amyloidosis secondary to rheumatoid arthritis. Rev Clin Esp. 1995;195:390–2.
   PubMed Web of Science ®Google Scholar
• Nakamura T, Yamamura Y, Tomoda K, Tsukano M, Shono M, Baba S. Efficacy of cyclophosphamide combined with prednis-olone in patients with AA amyloidosis secondary to rheumatoid arthritis. Clin Rheumatol. 2003;22:371–5.
   PubMed Web of Science ®Google Scholar
• Dember LM, Hawkins PN, Hanzenberg BPC, Gorevic PD, Merlini GM, Butrimiene I, et al. Eprodisate for the treatment of renal disease in AA amyloidosis. N Engl J Med. 2007;356:2349–60.
   PubMed Web of Science ®Google Scholar
• Gorevic PD, Hawkins PN, Skinner M, Nasonov EL, Butrimiene I, Benson MD, et al. Treatment with eprodisate results in a sig-nificant delay in the progression to dialysis/end-stage renal disease in amyloid A amyloidosis patients: analysis including retrieved follow-up data. Arthritis Rheum. 2007;56(Suppl):520.
   Google Scholar
• Lipsky PE, van der Heijde DMFM, St Clair EW, Furst DE, Breedveld FC, Kalden JR, et al. Infliximab and methotrexate in the treatment of rheumatoid arthritis. N Engl J Med. 2000;343:1594–602.
   PubMed Web of Science ®Google Scholar
• Klareskog L, van der Heiji D, de Jager JP, Gough A, Kalden J, Malaise M, et al. Therapeutic effect of the combination of eta-nercept and methotrexate compared with each treatment alone in patients with rheumatoid arthritis: double-blind randomized controlled trial. Lancet. 2004;363:675–81.
   PubMed Web of Science ®Google Scholar
• Smith GR, Tymmus KE, Falk M. Etanercept treatment of renal amyloidosis complicating rheumatoid arthritis. Intern Med J. 2004;34:570–2.
   Google Scholar
• Elkayam 0, Hawkins PN, Lachmann H, Yaron M, Caspi D. Rapid and complete resolution of proteinuria due to renal amy-loidosis in a patient with rheumatoid arthritis treated with infliximab. Arthritis Rheum. 2002;46:2571–3.
   Google Scholar
• Ortiz-Santamaria V, Valls-Roc M, Sanmarti M, Olive A. Anti-TNF treatment in secondary amyloidosis. Rheumatology. 2003;42:1425–6.
   PubMed Web of Science ®Google Scholar
• Gottenberg J-E, Merle-Vincent F, Bentaberry F, Allanore Y, Berenbaum F, Fautrel B, et al. Anti-tumor necrosis factor a therapy in fifteen patients with AA amyloidosis secondary to inflammatory arthritides. A followup report of tolerability and efficacy. Arthritis Rheum. 2003;48:2019–24.
   PubMed Web of Science ®Google Scholar
• Ravindran J, Shenker N, Bhalla AK, Lachmann H, Hawkins P. Case report: response in proteinuria due to AA amyloidosis but not Felty's syndrome in a patient with rheumatoid arthritis treated with TNF-a blockade. Rheumatology. 2004;43:669–72.
   Google Scholar
• Fernandes-Nebro A, Tomero E, Ortiz-Santamaria V, Castro MC, Olive A, de Haro M, et al. Treatment of rheumatic inflammatory disease in 25 patients with secondary amyloidosis using tumor necrosis factor alpha antagonists. Am J Med. 2005;118: 552–6.
   Google Scholar
• Okuda Y, Takasugi K. Successful use of a humanized anti-interleukin-6 receptor antibody, tocilianab, to treat amyloid A amyloidosis complicating juvenile idiopathic arthritis. Arthritis Rheum. 2006;54:2997–3000.
   PubMed Web of Science ®Google Scholar
• Nakamura T, Higashi S, Tomoda K, Tsukano M, Baba S. Effi-cacy of etanercept in patients with AA amyloidosis secondary to rheumatoid arthritis. Clin Exp Rheumatol. 2007;25:518–22.
   Google Scholar
• Jeong Y-S, Jun J-B, Kim T-H, Lee I-H, Bae S-C, Yoo D-H, et al. Successful treatment of protein-losing enteropathy due to AA amyloidosis with somatostatin analogue and high dose steroid in ankylosing spondylitis. Clin Exp Rheumatol. 2000;18:619–21.
   Google Scholar
• Fushimi T, Takahashi Y, Kashima Y, Fukushima K, Ishii W, Kaneko K, et al. Severe protein losing enteropathy with intractable diarrhea due to systemic AA amyloidosis, successfully treated with corticosteroid and octreotide. Amyloid. 2005;12:48–53.
   PubMed Web of Science ®Google Scholar
• Laiho K, Tiitinen S, Kaarela K, Helin H, Isomaki H. Secondary amyloidosis has decreased in patients with inflammatory joint disease in Finland. Clin Rheumatol. 1999;18:122–3.
   Google Scholar
• Kaipiainen-Seppanen 0, Myllykangas-Lousujarvi R, Lampainen E, Ikaheimo R. Intensive treatment of rheumatoid arthritis redu-ces need for dialysis due to secondary amyloidosis. Scand J Rheumatol. 2000;29:232–5.
   Google Scholar
• Hanzenberg BPC, van Rijswijk MH. Where has secondary amyloidosis gone? Ann Rheum Dis. 2000;59:577–9.
   Google Scholar
• American College of Rheumatology Subcommittee on Rheuma-toid Arthritis Guidelines. Guidelines for the management of rheumatoid arthritis: 2002 Update. Arthritis Rheum. 2002; 46:328–46.
   PubMed Web of Science ®Google Scholar
• Benditt EP, Eriksen N. Amyloid protein SAA is associated with high density lipoprotein from human serum. Proc Natl Acad Sci (USA) 1977;74:4025–8.
   PubMed Web of Science ®Google Scholar
• Banka CL, Yuan T, de Beer MC, Kindy M, Curtiss LK, de Beer FC. Serum amyloid A (SAA): influence on HDL-mediated cel-lular cholesterol efflux. J Lipid Res. 1995;36:1058–65.
   Google Scholar
• Rader DJ. Inflammatory markers of coronary risk. N Engl J Med. 2000;343:1179–82.
   PubMed Web of Science ®Google Scholar
• O'Brein KD, Chait A. Serum amyloid A. The "other" inflam-matory protein. CUIT Atheroscler Rep. 2006;8:62–8.
   PubMedGoogle Scholar
• Zhao Y, Zhou S, Heng C-K. Impact of serum amyloid A on tissue factor and tissue factor pathway inhibitor expression and activity in endothelial cells. Thromb Vase Biol. 2007;27:1645–50.
   Google Scholar
• Bokarewa M, Abrahamson M, Levshin N, Egesten A, Grubb A, Dahlberg L, et al. Cystatin C binds serum amyloid A, downregulating its cytokine-generating properties. J Rheumatol. 2007;34:1293–301.
   PubMed Web of Science ®Google Scholar
• Lee M-S, Yoo S-A, Cho C-S, Suh P-G, Kim W-U, Ryu SH. Serum amyloid A binding to formyl peptide receptor-like 1 induces synovial hyperplasia and angiogenesis. J Immunol. 2006;177: 5585–94.
   Google Scholar